Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Spooked investors still hiding

Watching Gensia Pharmaceutical Inc. stock languishing in the $24 range should cause some thoughtful investors to ask whether the company really deserves the $300 million sell off it suffered in September.

Investors were willing to hang on to GNSA above $35, waiting for Phase III data and a PLA filing on Arasine, its lead cardiovascular product. But the stock plummeted to the low $20s when investors interpreted European Phase III trial results as equivocal. And GNSA had hardly budged by last week, when the company announced that it had filed its PLA.

To explore the company's prospects and the gap in perceptions between Wall Street analysts and investors, BioCentury spoke to David

Read the full 1102 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers